男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Latest

China's first homegrown antiviral helps relieve COVID-19 flare-ups

By Wang Xiaoyu in Beijing and Shi Baoyin in Zhengzhou | chinadaily.com.cn | Updated: 2022-08-12 19:43
Share
Share - WeChat

China's first homegrown COVID-19 antiviral, approved by the top drug regulator last month and added to the national COVID-19 treatment protocol this week, has been shipped to regions coping with virus flare-ups, according to drug developers.

The oral drug named Azvudine is priced at 270 yuan ($40) per bottle, containing 35 one-milligram tablets, said Genuine Biotech based in Pingshan, Henan province in Central China.

Henan province is battling sporadic infections; the coastal province of Hainan and Xinjiang Uygur autonomous region are also experiencing new outbreaks. These provinces are among the first to receive the pills.

Azvudine obtained emergency use authorization from China's top drug regulator on July 25 and was included in the latest COVID-19 diagnosis and treatment guideline on Aug 9.

The guideline stipulates that the drug will be used to treat adult COVID-19 patients with moderate symptoms. Each patient will take 5 mg per day and each course of treatment will last no longer than 14 days, which would cost 540 yuan at most.

The National Healthcare Security Administration also confirmed on Friday that Azvudine is temporarily added to the national reimbursement list.

"Azvudine is the first domestic anti-COVID oral pill and our pricing strategy has prioritized affordability," the company told China Daily in a written interview.

The company's production base in Pingdingshan city, spanning 32,000 square meters, passed an inspection led by drug regulators in May and officially kicked off operation earlier this month. It said that the facility's annual manufacturing capacity currently stands at 1 billion tablets and is expected to reach 3 billion tablets in the future.

"In the meantime, we have cooperated with several pharmaceutical companies, including the Beijing Union Pharmaceutical Factory, so as to meet epidemic control demands," the company said.

The recent shipment destined for virus-hit areas is arranged by Genuine Biotech and Fosun Pharma, a Shanghai-based firm. The two companies struck a deal last month to advance commercialization of Azvudine on the mainland, and possibly in foreign countries in the future.

Azvudine was first approved in July 2021 to treat HIV patients and was found to be promising in tackling the COVID-19 disease. In a late-stage clinical trial, 40.4 percent of patients put on the antiviral showed improvement in symptoms seven days after first receiving the pill, compared with nearly 10.9 percent in the control group, the company said in a release in mid July.

The drug is also safe and could clear the virus in about five days, it said.

Chang Junbiao, vice-president of Zhengzhou University in Henan province and a leading researcher behind the pill, said that the development of small, molecular, oral pills could be "the last piece of the puzzle" in the fight against the virus because such drugs hold several advantages such as high convenience, few side effects and relatively low production costs.

Li Taisheng, an infectious disease expert at the Peking Union Medical College Hospital in Beijing, said that years of research on using Azvudine as an HIV drug has helped accelerated the launch of human trials to administer it to COVID-19 patients.

"As a new oral drug, it aids virus clearance, its toxicity is low and its price is very reasonable," he said at a forum on Friday.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 海淀区| 安阳县| 海晏县| 松原市| 玉龙| 菏泽市| 冀州市| 沈丘县| 宁陕县| 和林格尔县| 合肥市| 深州市| 南木林县| 南和县| 广宁县| 浪卡子县| 三明市| 麻城市| 清远市| 贵州省| 双柏县| 比如县| 乌苏市| 泽库县| 湘乡市| 千阳县| 卫辉市| 湖北省| 湘西| 望江县| 平和县| 安化县| 双鸭山市| 兰考县| 齐齐哈尔市| 如皋市| 盐山县| 贵德县| 云霄县| 康定县| 青州市|